Advertisement

Implantable Cardioverter Defibrillator: A Therapy for Everyone or for Selected Patients?

  • F. Bellocci
  • G. Pelargonio
  • M. G. Bendini
  • A. Intini
  • V. Affinito
  • O. Sacchetti
  • G. Bruni
  • A. S. Montenero
  • P. Zecchi
Conference paper

Abstract

The implantable cardioverter defibrillator (ICD) is an important and unique new method of potentially preventing recurrent sudden cardiac death (SCD) due to malignant ventricular arrhythmias (MVA).

Keywords

Cardiac Arrest Implantable Cardioverter Defibrillator Antiarrhythmic Drug Implantable Cardioverter Defibrillator Therapy Implantable Cardioverter Defibrillator Implantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kappenberger LJ (1995) Reflections on guidelines for the use of ICD. In: Camm J and Lindeman F (eds) Transvenous defibrillation and radiofrequency ablation. Futura, New York, pp 65–71Google Scholar
  2. 2.
    ACC/AHA Task Force Report (1991) Guidelines for implantation of cardiac pace-makers and antiarrhythmic devices. J Am Coll Cardiol 18: 1–8Google Scholar
  3. 3.
    Lehmann MH, Saksena S (1991) ICD in cardiovascular practice. Report of the policy conference of the Naspe. PACE 14: 969–979Google Scholar
  4. 4.
    Brugada P, Andries E (1991) The patient with malignant ventricular tachyarrhythmias can be offered optimal treatment on the basis of simple clinical variables. PACE 14: 1201–1204PubMedCrossRefGoogle Scholar
  5. 5.
    Fogoros RN, Elson J et al (1990) Efficacy of AICD in prolonging survival in patients with severe heart failure. J Am Coll Cardiol 16: 381–386PubMedCrossRefGoogle Scholar
  6. 6.
    Hentmorn RW (1991) Are the benefits of AICD overstimated by SCD rate? J Am Coll Cardiol 7: 1593–1595CrossRefGoogle Scholar
  7. 7.
    Kocks M, Eggeling T et al (1993) Pharmacological therapy in coronary artery disease. Eur Heart J 14: 107–112Google Scholar
  8. 8.
    Task Force of the European Society of Cardiology (1992) Guidelines for the use of ICD. Eur Heart J 13: 1304–1310Google Scholar
  9. 9.
    Winkle RA, Mead RH et al (1989) Long-term outcome with the AICD. J Am Coll Cardiol 13: 1353–1361PubMedCrossRefGoogle Scholar
  10. 10.
    Furman S (1989) AICD benefit. PACE 12: 399–400Google Scholar
  11. 11.
    Connolly S, Yusuf S (1992) Evaluation of ICD in survivors of cardiac arrest: the need for randomized trials. Am J Cardiol 89: 959–962CrossRefGoogle Scholar
  12. 12.
    Kim SG (1993) ICD therapy. Am J Cardiol 71: 1212–1218Google Scholar
  13. 13.
    Doval H, Nul D et al (1994) Randomized trial of low dose Amiodarone in severe congestive heart failure. Lancet 344: 493–499PubMedCrossRefGoogle Scholar
  14. 14.
    Teo K, Yusuf S et al (1993) Effect of prophylactic antiarrhythmic drug therapy in myocardial infarction. JAMA 270: 15981596Google Scholar
  15. 15.
    Mason JW (1993) A comparison of 7 antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 329: 452–457PubMedCrossRefGoogle Scholar
  16. 16.
    Steinbeck G, Andresen D et al (1992) A comparison of EPSguided antiarrhythmic drug therapy in patients with symptomatic sustained ventricular tachyarrhythmias. N Engl J Med 367: 987–993CrossRefGoogle Scholar
  17. 17.
    The CASCADE investigators (1993) The CASCADE study. Am J Cardiol 72: 280–286CrossRefGoogle Scholar
  18. 18.
    Singh BN (1994) ICD not the ultimate gold standard for gauging therapy of VT/VF. Am J Cardiol 73: 121–125CrossRefGoogle Scholar
  19. 19.
    Chove W, Kim SG et al (1994) Comparison of defibrillator therapy and other therapeutic modalities of VT/VF associated with coronary artery disease. Am J Cardiol 73: 1075–1080CrossRefGoogle Scholar
  20. 20.
    Saksena S (1992) Survavival of ICD recipients. Circulation 4: 1616–1620Google Scholar
  21. 21.
    Kim SG (1993) ICD therapy. Am J Cardiol 71: 1213–1216CrossRefGoogle Scholar
  22. 22.
    Sweeney MO, Ruskin JN (1994) Mortality benefits and the ICD. Circulation 89: 1851–1857PubMedGoogle Scholar
  23. 23.
    Zipes DP (1994) ICD: lifesaver or a device looking for a disease? Circulation 89: 2933–2937Google Scholar
  24. 24.
    Mower MM (1994) Letter to editor. PACE 17: 260–261CrossRefGoogle Scholar
  25. 25.
    Singer J (1994) Letter to editor. PACE 17: 261–263Google Scholar
  26. 26.
    Fogoros RN (1994) An AVID dissent. PACE 17: 1707–1710PubMedCrossRefGoogle Scholar
  27. 27.
    Epstein AE (1994) Reply to Editor. PACE 17: 262–265CrossRefGoogle Scholar
  28. 28.
    Connolly S (1994) An AVID dissent commentary. PACE 17: 1712–1715PubMedCrossRefGoogle Scholar
  29. 29.
    Siebels J, Cappato R et al (1993) ICD versus drug in cardiac arrest survivors. PACE 72: 103–106Google Scholar
  30. 30.
    Connolly S, Gent M et al (1993) Canadian ICD study. Am J Cardiol 72: 103–106CrossRefGoogle Scholar
  31. 31.
    The AVID investigators (1995) AVID: rationale, design and methods. Am J Cardiol 75: 470–474CrossRefGoogle Scholar
  32. 32.
    Weyer EF, Hauer RN et al (1995) Randomized study of ICD as first choice therapy versus conventional strategy in postinfarct sudden cardiac death survivors. Circulation 91: 2195–2203Google Scholar
  33. 33.
    Zipes DN (1995) Are ICD better than conventional antiarrhythmic drug for survivors of cardiac arrest? Circulation 91: 2115–2117PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 1996

Authors and Affiliations

  • F. Bellocci
    • 1
  • G. Pelargonio
    • 1
  • M. G. Bendini
    • 1
  • A. Intini
    • 1
  • V. Affinito
    • 1
  • O. Sacchetti
    • 1
  • G. Bruni
    • 1
  • A. S. Montenero
    • 1
  • P. Zecchi
    • 1
  1. 1.Istituto di CardiologiaUniversità Cattolica del Sacro CuoreRomeItaly

Personalised recommendations